JP2012530073A - カゼイン由来のプロテアーゼ阻害ペプチド - Google Patents

カゼイン由来のプロテアーゼ阻害ペプチド Download PDF

Info

Publication number
JP2012530073A
JP2012530073A JP2012515290A JP2012515290A JP2012530073A JP 2012530073 A JP2012530073 A JP 2012530073A JP 2012515290 A JP2012515290 A JP 2012515290A JP 2012515290 A JP2012515290 A JP 2012515290A JP 2012530073 A JP2012530073 A JP 2012530073A
Authority
JP
Japan
Prior art keywords
seq
peptide
casein
thr
peptidomimetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012515290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012530073A5 (enExample
Inventor
エリック チャールズ レイノルド
スチュアート ジェフリー ダッシュパー
Original Assignee
オーラル ヘルス オーストラリア ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009902841A external-priority patent/AU2009902841A0/en
Application filed by オーラル ヘルス オーストラリア ピーティーワイ リミテッド filed Critical オーラル ヘルス オーストラリア ピーティーワイ リミテッド
Publication of JP2012530073A publication Critical patent/JP2012530073A/ja
Publication of JP2012530073A5 publication Critical patent/JP2012530073A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012515290A 2009-06-19 2010-06-18 カゼイン由来のプロテアーゼ阻害ペプチド Pending JP2012530073A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2009902841 2009-06-19
AU2009902841A AU2009902841A0 (en) 2009-06-19 Protease inhibitory peptides
PCT/AU2010/000760 WO2010144968A1 (en) 2009-06-19 2010-06-18 Casein derived protease inhibitory peptides

Publications (2)

Publication Number Publication Date
JP2012530073A true JP2012530073A (ja) 2012-11-29
JP2012530073A5 JP2012530073A5 (enExample) 2013-07-04

Family

ID=43355610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012515290A Pending JP2012530073A (ja) 2009-06-19 2010-06-18 カゼイン由来のプロテアーゼ阻害ペプチド

Country Status (8)

Country Link
US (1) US20110104179A1 (enExample)
EP (2) EP2821414A1 (enExample)
JP (1) JP2012530073A (enExample)
KR (1) KR20120027535A (enExample)
CN (1) CN102459321A (enExample)
AU (1) AU2010262763A1 (enExample)
CA (1) CA2765423A1 (enExample)
WO (1) WO2010144968A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019115362A (ja) * 2019-04-24 2019-07-18 森永乳業株式会社 胃内酸性プロテアーゼ酵素活性阻害剤、ラクトフェリン組成物の製造方法、及びラクトフェリン組成物
WO2023228497A1 (ja) * 2022-05-24 2023-11-30 株式会社島津製作所 ニューログラニン関連ペプチド含有試料溶液の調製方法およびニューログラニン関連ペプチドの分析方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2652957A1 (en) 2006-06-27 2008-01-03 Oral Health Australia Pty Ltd. Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
CN102652831A (zh) 2007-07-12 2012-09-05 口腔健康澳洲私人有限公司 生物膜的免疫治疗
EP2638905B1 (en) 2007-07-12 2019-01-16 Oral Health Australia Pty Ltd Biofilm treatment
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN108840927B (zh) * 2018-06-06 2022-07-29 湖南生达生物科技有限公司 弹性蛋白酶抑制剂lnsp-i及其应用
US20220119496A1 (en) * 2019-02-15 2022-04-21 Andrzej Marek RAPAK Inhibitors of cysteine peptidases isolated from natural raw materials and use of the inhibitors in medicine and veterinary medicine
MX2021012778A (es) * 2019-04-26 2021-11-18 Colgate Palmolive Co Metodos y composiciones para reducir la tincion de composiciones antibacterianas para el cuidado bucal.
US11013677B2 (en) 2019-04-26 2021-05-25 Colgate-Palmolive Company Methods and compositions to reduce staining for antibacterial oral care compositions
KR20220034563A (ko) * 2020-09-11 2022-03-18 한국생명공학연구원 신규 치주 질환 특이 항체 및 이의 용도
KR102476515B1 (ko) * 2020-09-11 2022-12-12 한국생명공학연구원 치주 질환 특이 항체 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007519622A (ja) * 2003-12-19 2007-07-19 ザ・ユニヴァーシティ・オブ・メルボーン 抗菌性組成物
JP2008509073A (ja) * 2004-03-01 2008-03-27 ペプテラ ファーマスーティカルズ エルティーディー． カゼイン由来ペプチドおよびその治療的使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698327A (en) * 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
JP3567012B2 (ja) * 1995-03-28 2004-09-15 雪印乳業株式会社 新規ペプチド及びその利用
AUPP051497A0 (en) * 1997-11-24 1997-12-18 University Of Melbourne, The Antimicrobial peptides
EP1359157A1 (en) * 2002-04-29 2003-11-05 Société des Produits Nestlé S.A. Metallo-proteinase inhibitory agent
CA2481489A1 (en) * 2002-11-29 2004-06-17 Morinaga Milk Industry Co., Ltd. Cysteine protease inhibitor
MY162557A (en) * 2010-02-26 2017-06-15 Oral Health Australia Pty Ltd Treatment or prevention of infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007519622A (ja) * 2003-12-19 2007-07-19 ザ・ユニヴァーシティ・オブ・メルボーン 抗菌性組成物
JP2008509073A (ja) * 2004-03-01 2008-03-27 ペプテラ ファーマスーティカルズ エルティーディー． カゼイン由来ペプチドおよびその治療的使用

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019115362A (ja) * 2019-04-24 2019-07-18 森永乳業株式会社 胃内酸性プロテアーゼ酵素活性阻害剤、ラクトフェリン組成物の製造方法、及びラクトフェリン組成物
WO2023228497A1 (ja) * 2022-05-24 2023-11-30 株式会社島津製作所 ニューログラニン関連ペプチド含有試料溶液の調製方法およびニューログラニン関連ペプチドの分析方法
JPWO2023228497A1 (enExample) * 2022-05-24 2023-11-30
JP7831593B2 (ja) 2022-05-24 2026-03-17 株式会社島津製作所 ニューログラニン関連ペプチド含有試料溶液の調製方法およびニューログラニン関連ペプチドの分析方法

Also Published As

Publication number Publication date
AU2010262763A1 (en) 2012-01-19
EP2443143A4 (en) 2013-09-11
EP2443143A1 (en) 2012-04-25
CN102459321A (zh) 2012-05-16
EP2821414A1 (en) 2015-01-07
KR20120027535A (ko) 2012-03-21
US20110104179A1 (en) 2011-05-05
WO2010144968A1 (en) 2010-12-23
CA2765423A1 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
US20110104179A1 (en) Protease inhibitory peptides
US11793864B2 (en) Use of serine protease inhibitors in the treatment of skin diseases
JP5476297B2 (ja) バイオフィルム治療
AU2010224414B2 (en) Antimicrobial composition
US20140288007A1 (en) Gingipain inhibitory propeptides
US20120283174A1 (en) Antibiofilm glycopeptides
WO2014183168A1 (en) Inhibitory propeptides
US20050207995A1 (en) Methods and compositions for promoting oral health, and polypeptides useful for same
Class et al. Inventors: Eric Charles Reynolds (Carlton, AU) Eric Charles Reynolds (Carlton, AU) Stuart Geoffrey Dashper (Carlton, AU) Assignees: ORAL HEALTH AUSTRALIA PTY LTD
WO2018195637A1 (pt) Cistatina recombinante da cana-de-açúcar para redução do desgaste dentário erosivo e proteção contra cárie dentária
WO2012113037A1 (en) Method for inhibiting proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150609